"The primary safety and primary efficacy endpoints—which were preset in consideration with the FDA and all the societies—were met. You look at what we did, what we said, and using those definitions, filters are safe and effective."—Matthew S. Johnson, MD, FSIR, PRESERVE Principal Investigator
Host Warren Krackov, MD, FSIR, speaks with PRESERVE (Predicting the Safety and Effectiveness of Inferior Vena Cava Filters) Trial Principal Investigator Matthew S. Johnson, MD, FSIR, about the lessons learned from the trial's initial data, his collaboration with vascular surgery and others in the study, and more.
Related resources:
- Predicting the safety and effectiveness of Inferior Vena Cava Filters (PRESERVE): Outcomes at 12 months (Journal of Vascular and Interventional Radiology, April 2023)
- SIR/SVS Press Release on PRESERVE (Feb. 23, 2023)
- "Session recap: The SIR/SVS PRESERVE Trial" (SIR Today, March 6, 2023)
- Episode 10: The ongoing evolution of IVC filters (June 30, 2020)
Note: This episode was recorded on Aug. 8, 2023.
